scholarly journals A Clinical Quantitative Evaluation of Hepatobiliary Transport of [11C]Dehydropravastatin in Humans Using Positron Emission Tomography

2018 ◽  
Vol 46 (5) ◽  
pp. 719-728 ◽  
Author(s):  
Ken-ichi Kaneko ◽  
Masaaki Tanaka ◽  
Akira Ishii ◽  
Yumiko Katayama ◽  
Takayoshi Nakaoka ◽  
...  
Keyword(s):  
Positron Emission Tomography ◽  
Quantitative Evaluation ◽  
Emission Tomography ◽  
Hepatobiliary Transport ◽  
Positron Emission

Practical Synthesis of [18F]Pitavastatin and Evaluation of Hepatobiliary Transport Activity in Rats by Positron Emission Tomography

2020 ◽  
Vol 17 (6) ◽  
pp. 1884-1898
Author(s):  
Takayoshi Nakaoka ◽  
Yuta Uetake ◽  
Ken-ichi Kaneko ◽  
Takashi Niwa ◽  
Hidenori Ochiai ◽  
...  
Keyword(s):  
Positron Emission Tomography ◽  
Emission Tomography ◽  
Transport Activity ◽  
Hepatobiliary Transport ◽  
Positron Emission ◽  
Practical Synthesis

scholarly journals Quantitative evaluation of regional substrate metabolism in the human heart by positron emission tomography

1991 ◽  
Vol 18 (1) ◽  
pp. 101-111 ◽  
Author(s):  
Rodney J. Hicks ◽  
William H. Herman ◽  
Victor Kalff ◽  
Edgar Molina ◽  
Edwin R. Wolfe ◽  
...  
Keyword(s):  
Positron Emission Tomography ◽  
Quantitative Evaluation ◽  
Human Heart ◽  
Emission Tomography ◽  
Substrate Metabolism ◽  
Positron Emission

scholarly journals Quantitative evaluation of interim positron emission tomography in peripheral T-cell lymphoma

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Lars Kurch ◽  
Ulrich Dührsen ◽  
Andreas Hüttmann ◽  
Thomas W. Georgi ◽  
Osama Sabri ◽  
...  
Keyword(s):  
Positron Emission Tomography ◽  
T Cell ◽  
Quantitative Evaluation ◽  
Cell Lymphoma ◽  
Progression Free Survival ◽  
T Cell Lymphoma ◽  
Emission Tomography ◽  
Peripheral T Cell Lymphoma ◽  
Free Survival ◽  
Positron Emission

Abstract Background Interim [18F]fluoro-deoxyglucose-positron emission tomography predicts outcome in peripheral T-cell lymphoma (PTCL). We compared two quantitative evaluation methods. Methods Interim scans from 43 patients with anaplastic lymphoma kinase-negative PTCL from the ‘Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas’ trial were re-analyzed by qPET (relating residual lymphoma-related uptake to liver uptake) and ∆SUVmax (relating interim scan to baseline scan). The endpoint was progression-free survival. Results qPET and ∆SUVmax were closely correlated (Pearson’s r = 0.627). Up to the 60th percentile of values ranked by increasing residual activity, the positive predictive value for progression or death increased from 60 to 95%, with stable negative predictive values (NPV) of 60%. Beyond the 60th percentile, the NPV decreased to 40%. qPET ≥ 2 and ∆SUVmax < 50% identified high-risk populations comprising 41.9% and 39.5% of patients, with 3-year progression-free survival rates of 5.6% (95% confidence interval, 0.8–37.3) and 0%, respectively, as compared to 63.7% (47.4–85.8) and 61.3% (45.1–83.3) in low-risk patients. Conclusions qPET and ∆SUVmax identify large fractions of PTCL patients destined to experience treatment failure. qPET may be preferred because it requires a single PET scan, halving the diagnostic effort.

Sign in / Sign up

Export Citation Format

Share Document